Abstract 14688: Sarcopenia Is Independently Associated With Arterial Stiffness In Patients With Type 2 Diabetes Mellitus
Introduction: Sarcopenia is defined as an age-associated loss of muscle mass and function. It was recently reported that sarcopenia is often accompanied by diabetes mellitus (DM).
Hypothesis: Sarcopenia is associated with arterial stiffness in patients with type 2 DM.
Methods: We studied 150 hypertensives or possibly hypertensive patients in the Real BP study, an observational study of home BP telemonitoring system. As parameters of sarcopenia, we used circumference of the wrist, thigh (10cm above the patella) and lower leg, grip strength, and 6 minute-walk distance. Brachial-ankle pulse wave velocity (baPWV) was used as a parameter of arterial stiffness.
Results: The mean age of the patients was 71.0 yrs, 42.0% were female, and 47.3% had DM. In all patients, circumference of the thigh (r= -0.27, p=0.001), circumference of the lower leg (r= -0.29, p=0.001), grip strength (r= -0.29, p<0.001), and 6 minute-walk distance (r= -0.25, p<0.01) were negatively associated with baPWV. Then we divided the subjects by the presence of DM. In DM patients (mean age 68.5 yrs), circumference of the thigh (r= -0.38, p<0.01), circumference of the lower leg (r= -0.46, p<0.001), grip strength (r= -0.35, p<0.01), and 6 minute-walk distance (r= -0.26, p<0.05) were negatively associated with baPWV. In multiple regression analysis, circumferences of the thigh and lower leg were associated with baPWV. However, in non-DM patients (mean age 73.1 yrs), although grip strength (r= -0.25, p<0.05) and 6 minute-walk distance (r= -0.24, p<0.05) were negatively associated with baPWV, these associations did not remain significant after adjusting for covariates.
Conclusions: The parameters of sarcopenia were independently associated with the measure of arterial stiffness. This association was stronger in patients with DM. Impaired glucose metabolism may play an important role as a mechanism behind sarcopenia and arterial stiffness.
Author Disclosures: Y. Imaizumi: None. K. Eguchi: None. M. Yamamoto: None. R. Kaku: None. K. Kario: Research Grant; Significant; Teijin Pharma Limited, OMRON HEALTHCARE Co., Ltd., FUKUDA DENSHI, Bayer Yakuhin Ltd., A &D Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED., MOCHIDA PHARMACEUTICAL CO., LTD, EA pharma, Otsuka Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan Inc., Mitsubishi Tanabe Pharma Corporation., Medtronic Japan Co., Ltd.. Honoraria; Modest; Mitsubishi Tanabe Pharma Corporation., Kyowa Hakko Kirin Co., Ltd., Bayer Yakuhin Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Sanofi K.K., TERUMO CORPORATION, Bristol-Myers K.K., Kowa Pharmaceutical Co. Ltd., SANWA KAGAKU KENKYUSHO CO.,LTD., MSD K.K., Actelion Pharmaceuticals Japan, Abott Japan, OMRON HEALTHCARE Co., Ltd., Century Medical Inc., TOA EIYO LTD., MOCHIDA PHARMACEUTICAL CO., LTD, Sumitomo Dainippon Pharma Co., Ltd.. Honoraria; Significant; Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, LIMITED., OMRON HEALTHCARE Co., Ltd..
- © 2016 by American Heart Association, Inc.